World News: 21:15 GMT Monday 11th February 2019. [Kadmon Holdings, Inc. via Globe Newswire via SPi World News]
NEW YORK, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today announced the appointment of Steven Meehan as Executive Vice President, Chief Financial Officer. Mr. Meehan, who has served as a member of the Board of Directors at Kadmon since 2017, has over 25 years of financial leadership experience spanning corporate strategy, mergers and acquisitions, capital raising and financial planning and analysis.
Mr. Meehan will provide strategic leadership to Kadmon’s finance organization and will assume responsibility for the Company’s internal controls and business processes. Mr. Meehan will step down as a member of the Board at Kadmon as he assumes his appointment as CFO.
“We are fortunate to bring Steve’s corporate finance expertise to Kadmon as we advance our clinical pipeline and prepare for several key milestones this year,” said Harlan W. Waksal, M.D., President and CEO at Kadmon. “Steve’s operational leadership and experience in M&A, financial planning and capital raising make him invaluable to our management team and long-term strategy.”
Dr. Waksal noted, “Steve’s experience on our Board has provided him with a deep understanding of Kadmon that will help us continue to accomplish our goals. I am grateful to Steve for his contributions to Kadmon and look forward working with him in his new role as CFO.”
Mr. Meehan previously served as a partner in the Healthcare Group of Moelis & Company, leading the effort in Life Sciences and Advanced Diagnostics. Prior to Moelis, Mr. Meehan was Head of Life Sciences within the Global Healthcare Group in the New York office of UBS Investment Bank (UBS). During his tenure at UBS, Mr. Meehan was Chief Executive Officer of UBS Russia and the former Soviet Union across all businesses, including securities, banking and wealth management. He was also a member of the UBS Group’s EMEA Management Committee. During his investment banking career, Mr. Meehan also held senior roles in M&A, leveraged finance and capital markets at Salomon Smith Barney, NatWest Securities and Drexel Burnham Lambert. Mr. Meehan holds a B.S. in Business Administration/Finance from the University of Massachusetts at Lowell.
Kadmon Holdings, Inc. is a fully integrated biopharmaceutical company developing innovative product candidates for significant unmet medical needs. Our product pipeline is focused on inflammatory and fibrotic diseases.
Globe Newswire: 21:15 GMT Monday 11th February 2019
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.